Targeted therapies in rheumatoid arthritis: Focus on rituximab.
B-cell depletion is a new strategy for treating patients with rheumatoid arthritis (RA). In the past years, several studies have proven the efficacy of anti-CD20 mediated B-cell depletion with rituximab (Mabthera((R))) in RA patients who failed TNF-blocking therapy. The important role of B-cells in the pathogenesis of RA is deducted from the specific detection of autoantibodies in RA and infiltration of B-cells and plasma cells in inflamed synovium. Pharmacological studies in RA patients treated with rituximab showed that half-life was approximately 3 weeks leading to a 6- to 8-month period of B-cell depletion in peripheral blood. Rituximab treatment led to significant improvements in disease activity of RA patients and the current review summarizes the results from phase III, randomized clinical trials that have been performed. Lastly, data on safety and quality of life are summarized. Although relatively low numbers of RA patients have been treated and long-term data are lacking, current data thus far suggest a relatively good safety profile for rituximab. Future studies will need to focus on predicting responsiveness to rituximab, investigating efficacy of re-treatment with rituximab and extending data on safety and patient-focused outcomes.
Teng
Y K
YK
Department of Rheumatology, Leiden University Medical Center, The Netherlands.
Huizinga
T W
TW
van Laar
J M
JM
Crit Rev Oncol Hematol. 2001 Oct;40(1):3-16
11578912
Arthritis Rheum. 2001 Apr;44(4):754-60
11315914
Arthritis Rheum. 1994 Nov;37(11):1647-55
7980676
Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53
17069520
J Immunol. 2006 Jul 1;177(1):362-71
16785532
Proc Soc Exp Biol Med. 1948 May;68(1):1-6
18863659
N Engl J Med. 2002 Jan 24;346(4):235-42
11807147
Biochemistry. 2005 Nov 22;44(46):15150-8
16285718
Curr Dir Autoimmun. 2005;8:175-92
15564721
N Engl J Med. 2004 Jun 17;350(25):2572-81
15201414
Arthritis Rheum. 2004 Jun;50(6):1897-908
15188366
Ann Rheum Dis. 2007 Oct;66(10):1356-62
17293364
N Engl J Med. 2000 Nov 30;343(22):1586-93
11096165
Bone Marrow Transplant. 1992 Jun;9(6):395-408
1628122
Ann Intern Med. 2007 Mar 20;146(6):406-15
17371885
N Engl J Med. 1999 Jan 28;340(4):253-9
9920948
Ann Rheum Dis. 2004 Sep;63(9):1085-9
15308517
Arthritis Rheum. 2008 Feb;58(2):634; author reply 634
18240246
Rheumatology (Oxford). 2007 Jan;46(1):29-36
16735454
Arthritis Rheum. 2006 Aug;54(8):2356-67
16868991
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Oncogene. 2003 Oct 20;22(47):7359-68
14576843
Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii
15172048
Arthritis Res Ther. 2005;7(3):R569-80
15899044
N Engl J Med. 2004 Jun 17;350(25):2546-8
15201410
J Rheumatol. 2002 Aug;29(8):1631-8
12180721
J Clin Pharmacol. 2005 Jul;45(7):792-801
15951469
Arthritis Res Ther. 2004;6(3):107-11
15142259
Nat Immunol. 2001 Sep;2(9):764-6
11526379
Anticancer Drugs. 2002 Nov;13 Suppl 2:S3-10
12710585
Semin Oncol. 2002 Feb;29(1S2):2-9
28140087
Ann Rheum Dis. 2005 Oct;64(10):1510-2
15800005
Rheumatology (Oxford). 2000 Sep;39(9):975-81
10986302
Ann Rheum Dis. 2004 Oct;63(10):1218-21
15361374
Curr Opin Rheumatol. 2003 May;15(3):246-52
12707577
Arthritis Rheum. 2007 Mar;56(3):772-8
17328049
Ann Rheum Dis. 2005 Oct;64(10):1516-7
16162906
Ann Rheum Dis. 2005 Apr;64(4):537-43
15769913
Arthritis Rheum. 2006 Sep;54(9):2793-806
16947627
Ann Rheum Dis. 2002 Oct;61(10):883-8
12228157
Arthritis Rheum. 2006 May;54(5):1390-400
16649186
Rheumatology (Oxford). 2001 Feb;40(2):205-11
11257159
Lancet. 1999 Dec 4;354(9194):1932-9
10622295
Ther Apher. 2001 Apr;5(2):79-83
11354303
J Rheumatol. 2004 Mar;31(3):482-8
14994391
Arthritis Rheum. 2006 Feb;54(2):613-20
16447239
Science. 1957 Jul 26;126(3265):162-3
13442661
Arthritis Rheum. 2006 Aug;54(8):2377-86
16869000
Intern Med. 2005 Nov;44(11):1122-6
16357447